Search
Elacridar
go.drugbank.com/drugs/DB04881InvestigationalIn many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline.
Vapreotide
go.drugbank.com/drugs/DB04894InvestigationalVapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.
Tesmilifene
go.drugbank.com/drugs/DB04905InvestigationalTesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast
Afamelanotide
go.drugbank.com/drugs/DB04931Approved[L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer … Afamelanotide is a first-in-class, synthetic, 13-amino acid peptide analogue of the endogenous alpha melanocyte-stimulating hormone (α-MSH).
Categories: Compounds used in a research, industrial, or household settingEritoran
go.drugbank.com/drugs/DB04933InvestigationalEritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.
Denufosol
go.drugbank.com/drugs/DB04983InvestigationalA new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol. … Denufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial.
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigationalElafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis.
Piclamilast
go.drugbank.com/drugs/DB01791ExperimentalPiclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. … The structure for piclamilast was first elucidated in a 1995 European patent application and exhibits the structural functionalities of cilomilast and roflumilast.
Bacteriochlorophyll A
go.drugbank.com/drugs/DB01853ExperimentalA specific bacteriochlorophyll that is similar in structure to CHLOROPHYLL A.
Synonyms: Bacterio-chlorophyll A, Bacteriochlorophyll APimelic Acid
go.drugbank.com/drugs/DB01856ExperimentalA group of compounds that are derivatives of heptanedioic acid with the general formula R-C7H11O4. [PubChem]